undamentalytics Newsletter
Sign in

Sonoma Pharmaceuticals, Inc. cash flow statement

In fiscal 2026, Sonoma Pharmaceuticals, Inc.'s operations generated −$3.9m of cash; it spent $192,000 on capital projects, leaving free cash flow of −$4.1m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2011Mar 20112012Mar 20122013Mar 20132014Mar 20142015Mar 20152016Mar 20162017Mar 20172018Mar 20182019Mar 20192020Mar 20202021Mar 20212022Mar 20222023Mar 20232024Mar 20242025Mar 20252026Mar 2026LTMJun 2026
Cash from operations−4−41−5−7−9−8−12−12−5−3−4−6−2−0−4−3
Depreciation and amortisation00000000000000000
Stock-based pay23212223210011000
Capital spending00010000000000000
Free cash flow−5−41−5−7−9−9−13−12−5−4−4−6−2−0−4−3
Free cash flow after stock pay−7−7−1−7−9−11−11−15−13−6−4−5−7−3−0−4−3
Shares issued—2537601110832304

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: BDMD vs SNOASNOA vs VVOSNEPH vs SNOASNOA vs ZJYL

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Sonoma Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Sonoma Pharmaceuticals, Inc.